AMENDMENTS TO THE CLAIMS

Please cancel claims 1-37 without prejudice.

Please add claims 38-50.

A complete list of claims as currently amended follows:

1-37. (canceled).

38. (new) A once-a-day composition comprising:

(a) an immediate release component comprising bupropion or a pharmaceutically acceptable salt thereof;

(b) an enteric release component comprising bupropion or a pharmaceutically acceptable salt thereof and a pH dependent coating polymer; and

(c) a sustained release component comprising bupropion or a pharmaceutically acceptable salt thereof and a water insoluble coating polymer wherein said composition contains 75 to 450 mg of bupropion or a pharmaceutically acceptable salt thereof and provides an in vivo plasma profile selected from:

(a) a mean C_{max} of at least 50.0 ng/ml;

(b) a mean $AUC_{0\text{-}inf}$ of greater than approximately 500.0 ng·hr/ml; and

(c) a mean T_{max} of between approximately 5.0 hours and 8.5 hours based upon a single dose administration of a composition containing 150 mg of bupropion or a pharmaceutically acceptable salt.

39. (new) The composition of claim 38 wherein the immediate release component is a powder, granule or uncoated active pellet.

40. (new) The composition of claim 38 wherein said enteric release component is a pellet comprising a core containing the buproprion or pharmaceutically acceptable salt thereof and the pH dependent coating polymer is applied to the core.

41. (new) The composition of claim 38 wherein said sustained release component is a pellet comprising a core containing the buproprion or pharmaceutically acceptable salt thereof and the water insoluble coating polymer is applied to the core .

42. (new) The composition of claim 38 wherein said pH dependent coating polymer is selected from the group consisting of shellac, methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and mixtures thereof.

43. (new). The composition of claim 38 wherein said water insoluble coating polymer is selected from the group consisting of ethyl cellulose, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate and mono-, di- and tri-cellulose arylates.

44. (new) The composition of claim 38 wherein the composition is a tablet.

45. (new) The composition of claim 38 wherein the composition is a capsule.

46. (new) The composition of claim 38 wherein the sustain release component further comprises a methacrylic acid copolymer.

47. (new) The composition of claim 38 wherein the mean C_{max} is less than 90 ng/ml.

48. (new) The composition of claim 47 wherein the mean Cmax is less than 80 ng/ml.

49. (new) The composition of claim 48 wherein the mean C_{max} is less than 70 ng/ml.

50. (new) The composition of claim 38 wherein the mean T_{max} is 5.1 hours to 8.1 hours.